BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Ultimate Trader

1 year 40%, 2 years 50% and *3 years 60%

*Across 3 years $3395.52 only $1358.21

ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,998.67
-0.38%
US Tech 100
20,193.60
-0.88%
Dow Jones
44,738.84
-0.27%
Brent Oil
72.385
-0.09%
Bitcoin
96,544.95
4.97%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. AN2 Therapeutics Inc (ANTX)

  7. AN2 Therapeutics Inc (ANTX) News

AN2 Therapeutics Inc

AN2 Therapeutics Inc (ANTX)

NASDAQ
1.36
-0.03
( -2.16% )
Updated: 15:33:03
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

ANTX News

Official News Only

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
August 13 2024
ANTX (-2.16%)

Form 8-K - Current report
Edgar (US Regulatory)
August 13 2024
ANTX (-2.16%)

Form 8-K - Current report
Edgar (US Regulatory)
August 08 2024
ANTX (-2.16%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
July 12 2024
ANTX (-2.16%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
May 14 2024
ANTX (-2.16%)

Form 8-K - Current report
Edgar (US Regulatory)
May 14 2024
ANTX (-2.16%)

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Edgar (US Regulatory)
February 13 2024
ANTX (-2.16%)

Form 8-K - Current report
Edgar (US Regulatory)
February 12 2024
ANTX (-2.16%)

ANTX Discussion

View Posts
stocksrising stocksrising 6 days ago
Open market purchase always welcomed :)..even if tiny 😜

Common Stock-CEO
11/18/2024
50,000
A
$0.9994
1,065,76
👍️0
TrendTrade2016 TrendTrade2016 1 week ago
ANTX MINI BIO BEAST
👍️ 1
stocksrising stocksrising 2 weeks ago
I haven’t done much DD on this bio, but it seems they have several readouts within 6-12mos. that could propel stock higher (especially with the $$$ runway position)… as you know, any biotech is risky but I like the odds on this one and starter position is small for now…I did copy this from release that I found appealing:

Boron Chemistry Pipeline

Additional development programs are underway and focused on targets in infectious diseases and oncology with high unmet needs. The Company anticipates delivering up to three development compounds in 2025.

Global Health

In October, the Company announced that it received a second-year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel boron containing small molecules for the treatment of tuberculosis and malaria. The Company will continue its efforts to tackle global health disease through non-dilutive funding.
👍️0
eyeownu eyeownu 2 weeks ago
NOPE. took my looses moved them over to $EBS and made it all back. do you notice anything promising that warrants investing in this company besides the cash on hand?
👍️0
stocksrising stocksrising 2 weeks ago
Picked up a bit more down here at $1ish, you still in??
👍️0
Monksdream Monksdream 4 months ago
ANTX new 52 week low
👍️0
Monksdream Monksdream 4 months ago
ANTX under $3
👍️0
eyeownu eyeownu 4 months ago
looking good
👍️0
glenn1919 glenn1919 5 months ago
ANTX..............https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783
👍️0
GO4AWILDRIDE GO4AWILDRIDE 8 months ago
FROM 3/28 NEWS:

Cash, cash equivalents, and investments of $134.5 million at December 31, 2023

GO4AWILDRIDE
👍️0
GO4AWILDRIDE GO4AWILDRIDE 8 months ago
THE FOLLOWING FROM THE 3/28 NEWS:

“AN2’s cash position remains strong as we advance our innovative boron-based pipeline. Following the recent meeting of the independent Data Safety Monitoring Board, we continue to believe in the potential of epetraborole to become an important component of the backbone therapy for NTM lung disease,” said Eric Easom, Co-Founder, President and Chief Executive Officer. “Patients enrolled in the epetraborole Phase 2/3 trial in treatment refractory lung disease caused by MAC continue to be dosed while new enrollment in the Phase 3 part of the trial remains paused. Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer. Analysis of the baseline patient demographics from the trial show a highly complex and refractory patient population, which we plan to discuss with the FDA in the coming months.”

GO4AWILDRIDE
👍️0
GO4AWILDRIDE GO4AWILDRIDE 8 months ago
Monksdream

Did you read the 3/28 news from the compay?

Seems like the market is looking to chase the price up.

GLTU

GO4AWILDRIDE
👍️0
GO4AWILDRIDE GO4AWILDRIDE 8 months ago
Monksdream

Seems like a nice rebound is starting to occur.

GLTU

GO4AWILDRIDE
👍️0
Monksdream Monksdream 9 months ago
ANTX new 52 week low
👍️0
Monksdream Monksdream 9 months ago
ANTX new 52 week low
👍️0
Monksdream Monksdream 9 months ago
ANTX new 52 week low
👍️0

Your Recent History

NASDAQ
ANTX
AN2 Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 65%* for Small Cap Pro

1 year 40%, 2 years 50% and *3 years 65%

*Across 3 years $2158.56 only $755.50